AMPK may be involved in the metformin-induced modulation of lncRNA because metformin has been shown to inhibit endothelial cell proliferation and atherosclerosis by attenuating the lncRNA TUG1 by activating the AMPK/mammalian target of rapamycin (mTOR) pathway [52]. Here, PRKAA2 is linked to atherosclerosis.